Table 2.

Chemoradiotherapy containing S-1 and CDDP (cisplatin) for locally advanced non-small cell lung cancer (NSCLC).

Study	Phase	Schedule	n	MST (months)	2-year survival (%)	Response rate (%)
[Kaira et al. 2009]	I	S-1; 30 mg/m2, bid, days 1–14	10	N.R.	–	100
		CDDP; 40 mg/m2, days 1, 8,
		Q 21 days × 4 cycles
		TRT; 60 Gy/30 fr.*
[Ohyanagi et al. 2009]	II	S-1; 40 mg/m2, bid, days 1–14	48	33.1	56	87.5
		CDDP; 60 mg/m2, day 8,
		Q 21 days × 4 cycles
		TRT; 60 Gy/30 fr.
[Ichinose et al. 2011]	II	S-1; 40 mg/m2, bid, days 1–14	50	20	70	84
		CDDP; 60 mg/m2, day 8,
		Q 21 days × 4 cycles
		TRT; 60 Gy/30 fr.

bid, twice daily; DTX, docetaxel; MST, median survival time; TRT, thoracic radiotherapy.

^*Recommended dose for phase II study.